|
ANNX | Annexon, Inc. |
|
|
ANNX | Annexon, Inc. |
| Pharmaceutical Preparations |
| Book value per $ invested | $ 0.32 |
| Leverage | 29.54% |
| Market Cap | $ 501.8m |
| PE | 0.00 |
| Dividend Yield | 0.00% |
| Profit | $ -206.3m |
| Margin | 0.00% |
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for autoimmune and neurodegenerative diseases. The company is headquartered in South San Francisco, California.